JP2024535053A5 - - Google Patents
Info
- Publication number
- JP2024535053A5 JP2024535053A5 JP2024516963A JP2024516963A JP2024535053A5 JP 2024535053 A5 JP2024535053 A5 JP 2024535053A5 JP 2024516963 A JP2024516963 A JP 2024516963A JP 2024516963 A JP2024516963 A JP 2024516963A JP 2024535053 A5 JP2024535053 A5 JP 2024535053A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- polysorbate
- histidine
- sucrose
- vista
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244986P | 2021-09-16 | 2021-09-16 | |
| US63/244,986 | 2021-09-16 | ||
| PCT/EP2022/075849 WO2023041745A1 (en) | 2021-09-16 | 2022-09-16 | Treatment and prevention of cancer using vista antigen-binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535053A JP2024535053A (ja) | 2024-09-26 |
| JP2024535053A5 true JP2024535053A5 (enExample) | 2025-09-19 |
Family
ID=83995418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516963A Pending JP2024535053A (ja) | 2021-09-16 | 2022-09-16 | Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250313631A1 (enExample) |
| EP (1) | EP4401772A1 (enExample) |
| JP (1) | JP2024535053A (enExample) |
| KR (1) | KR20240058149A (enExample) |
| CN (1) | CN119384293A (enExample) |
| TW (1) | TW202328196A (enExample) |
| WO (1) | WO2023041745A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025125495A1 (en) | 2023-12-13 | 2025-06-19 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| GB202402901D0 (en) * | 2024-02-29 | 2024-04-17 | Cambridge Entpr Ltd | reventative treatment of hrd associated cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CN103119054B (zh) | 2010-03-26 | 2017-01-18 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| ES2929575T3 (es) | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| DK3049441T3 (da) * | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1-antistofformuleringer |
| US10273301B2 (en) | 2013-12-24 | 2019-04-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| MX2017007136A (es) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
| AU2016303485A1 (en) | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immunomodulation |
| US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| KR20250024129A (ko) * | 2018-07-20 | 2025-02-18 | 피에르 파브르 메디카먼트 | Vista의 수용체 |
-
2022
- 2022-09-16 KR KR1020247011389A patent/KR20240058149A/ko active Pending
- 2022-09-16 EP EP22793680.4A patent/EP4401772A1/en active Pending
- 2022-09-16 CN CN202280076540.0A patent/CN119384293A/zh active Pending
- 2022-09-16 TW TW111135206A patent/TW202328196A/zh unknown
- 2022-09-16 JP JP2024516963A patent/JP2024535053A/ja active Pending
- 2022-09-16 WO PCT/EP2022/075849 patent/WO2023041745A1/en not_active Ceased
- 2022-09-16 US US18/692,314 patent/US20250313631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers | |
| Phan et al. | P38 kinase in gastrointestinal cancers | |
| Wickström et al. | Aminopeptidase N (CD13) as a target for cancer chemotherapy | |
| JP2021120406A5 (ja) | 癌を治療するための組み合わせ物 | |
| Monk et al. | Anti-angiogenesis agents in metastatic or recurrent cervical cancer | |
| Wu et al. | Anti-angiogenic therapeutic drugs for treatment of human cancer | |
| US8664276B2 (en) | Stilbene analogs and methods of treating cancer | |
| US20250325553A1 (en) | Methods of treating cancer | |
| US9828412B2 (en) | Short peptide targeting EPS8 binding with EGFR and use thereof | |
| De Mey et al. | Antidiabetic biguanides radiosensitize hypoxic colorectal cancer cells through a decrease in oxygen consumption | |
| Sun et al. | Unveiling the future of breast cancer therapy: cutting-edge antibody-drug conjugate strategies and clinical outcomes | |
| Seo | Dual inhibitors against topoisomerases and histone deacetylases | |
| AU2016318136B2 (en) | Selection of patients for combination therapy | |
| Wang et al. | Current development of glioblastoma therapeutic agents | |
| Tong et al. | The emerging roles of histone demethylases in cancers | |
| JP2025503971A5 (enExample) | ||
| Iizuka et al. | The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma | |
| Cina et al. | A novel lipid nanoparticle nbf-006 encapsulating glutathione s-transferase p siRNA for the treatment of KRAS-driven non–small cell lung cancer | |
| Gold et al. | Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors | |
| Zhang et al. | Pancreatic cancer: recent progress of drugs in clinical trials | |
| Yuan et al. | ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S | |
| Liu et al. | Biomimetic anlotinib-loaded FePc-silicate nanoparticles for sonodynamic and immunotherapy in non-small cell lung cancer via dual PD-L1 modulation | |
| CA3217458A1 (en) | Sirna constructs for inhibiting gene expression in targeted cancer cells | |
| Hu et al. | Oxycodone stimulates normal and malignant hematopoietic progenitors via opioid-receptor-independent-β-catenin activation | |
| Yuan et al. | Small-molecule inhibitor of Fam20C in combination with paclitaxel suppresses tumor growth by LIF-JAK2/STAT3-modulated apoptosis in triple-negative breast cancer |